MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.32
+0.12
+1.46%
Opening 13:10 09/16 EDT
OPEN
8.21
PREV CLOSE
8.20
HIGH
8.34
LOW
8.12
VOLUME
58.84K
TURNOVER
--
52 WEEK HIGH
11.68
52 WEEK LOW
6.99
MARKET CAP
360.83M
P/E (TTM)
-34.6378
1D
5D
1M
3M
1Y
5Y
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
/PRNewswire/ --  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming  to provide a global perspective on CytoSorb blood purification therapy in COVID-19 patients on , at / . ...
PR Newswire - PRF · 2d ago
A Trio of Stocks Growing Revenue Per Share Fast
GuruFocus News · 3d ago
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces key sepsis-relate...
PR Newswire · 3d ago
CytoSorbents Announces Filing Of Investigational Device Exemption For US Clinical Trial On Apixaban And Rivaroxaban Removal By DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery
 CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption
Benzinga · 6d ago
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
/PRNewswire/ --  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Ex...
PR Newswire - PRF · 6d ago
Cytosorbents Files for Investigational Device Exemption With US FDA for DrugSorb-ATR System; Shares Gain Pre-Bell
MT Newswires · 6d ago
CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
/PRNewswire/ --  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces a special Company webinar highlighting  th...
PR Newswire - PRF · 09/08 20:15
A Look At The Intrinsic Value Of Cytosorbents Corporation (NASDAQ:CTSO)
In this article we are going to estimate the intrinsic value of Cytosorbents Corporation ( NASDAQ:CTSO ) by estimating...
Simply Wall St. · 09/08 11:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTSO stock price target is 14.60 with a high estimate of 16.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 149
Institutional Holdings: 18.48M
% Owned: 42.62%
Shares Outstanding: 43.37M
TypeInstitutionsShares
Increased
24
1.61M
New
17
452.24K
Decreased
38
1.65M
Sold Out
11
401.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.86%
Healthcare Equipment & Supplies
-0.52%
Key Executives
Non-Executive Chairman/Independent Director
Al Kraus
President/Chief Operating Officer
Vincent Capponi
Chief Executive Officer/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Scientific Officer
Efthymios Deliargyris
Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
No Data
  • All
  • Financials
  • Insiders
More
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.